seen from Malaysia
seen from Germany
seen from China
seen from United States
seen from China
seen from United States
seen from China
seen from Germany
seen from China
seen from China
seen from Romania
seen from Singapore
seen from China
seen from United States
seen from United Kingdom
seen from Australia
seen from Moldova
seen from China
seen from United States
seen from Venezuela
Top News from ASCO GI 2018
Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
January 18, 2018
Exelixis, Inc. and Ipsen have announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC) at the 2018 ASCO-GI…
View On WordPress
Top News from 2017 San Antonio Breast Cancer Symposium (SABCS)
Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
December 06, 2017
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, has announced results from a ground-breaking validation study to better define the risk of breast cancer in women of European ancestry who test negative for a hereditary…
View On WordPress
Top Pharma News - December 2016
Top Pharma News – December 2016
ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer
Dec 6, 2016
Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented…
View On WordPress
ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer
ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer
Dec 6, 2016
Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the ABOUND trials during the IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the…
View On WordPress
